Comment on

• The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

  Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM. Macaskill EJ, et al. Breast Cancer Res Treat. 2011 Aug;128(3):725-34. doi: 10.1007/s10549-010-0967-z. Epub 2010 Oct 13. Breast Cancer Res Treat. 2011. PMID: 20941539 Clinical Trial.
• "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?

  Margariti N, Fox SB, Bottini A, Generali D. Margariti N, et al. Breast Cancer Res Treat. 2011 Aug;128(3):599-606. doi: 10.1007/s10549-010-0986-9. Epub 2010 Oct 14. Breast Cancer Res Treat. 2011. PMID: 20945086 Review.
• Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.

  Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O. Pérez-Tenorio G, et al. Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi: 10.1007/s10549-010-1058-x. Epub 2010 Oct 16. Breast Cancer Res Treat. 2011. PMID: 20953835